MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

Search

ESPERION THERAPEUTICS INC

Abrir

SetorSaúde

0.91 5.81

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.85

Máximo

0.92

Indicadores-chave

By Trading Economics

Rendimento

8.2M

-21M

Vendas

17M

69M

EPS

-0.101

Margem de lucro

-30.845

Funcionários

304

EBITDA

9.5M

-4.9M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+638.64% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-166M

169M

Abertura anterior

-4.9

Fecho anterior

0.91

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

ESPERION THERAPEUTICS INC Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de abr. de 2025, 23:54 UTC

Ações em Alta

Stocks to Watch: Alphabet, Intel, AppFolio

24 de abr. de 2025, 23:51 UTC

Conversa de Mercado

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 de abr. de 2025, 23:46 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 de abr. de 2025, 23:46 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 de abr. de 2025, 23:37 UTC

Principais Notícias

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 de abr. de 2025, 23:36 UTC

Principais Notícias

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 de abr. de 2025, 23:13 UTC

Principais Notícias
Ganhos

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 de abr. de 2025, 23:09 UTC

Principais Notícias

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 de abr. de 2025, 23:02 UTC

Aquisições, Fusões, Aquisições de Empresas

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 de abr. de 2025, 23:02 UTC

Aquisições, Fusões, Aquisições de Empresas

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 de abr. de 2025, 22:51 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 de abr. de 2025, 22:48 UTC

Principais Notícias

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 de abr. de 2025, 22:47 UTC

Conversa de Mercado

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 de abr. de 2025, 22:38 UTC

Conversa de Mercado
Ganhos

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 de abr. de 2025, 22:24 UTC

Ganhos

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 de abr. de 2025, 22:24 UTC

Ganhos

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 de abr. de 2025, 22:24 UTC

Conversa de Mercado
Ganhos

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 de abr. de 2025, 22:23 UTC

Ganhos

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 de abr. de 2025, 22:11 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

24 de abr. de 2025, 22:11 UTC

Conversa de Mercado
Ganhos

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 de abr. de 2025, 22:09 UTC

Principais Notícias
Ganhos

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 de abr. de 2025, 22:00 UTC

Conversa de Mercado
Ganhos

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 de abr. de 2025, 21:39 UTC

Principais Notícias

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 de abr. de 2025, 21:24 UTC

Principais Notícias
Ganhos

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 de abr. de 2025, 21:24 UTC

Principais Notícias
Ganhos

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 de abr. de 2025, 21:23 UTC

Principais Notícias
Ganhos

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 de abr. de 2025, 21:04 UTC

Ganhos

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 de abr. de 2025, 21:03 UTC

Ganhos

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 de abr. de 2025, 21:03 UTC

Ganhos

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 de abr. de 2025, 21:02 UTC

Ganhos

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Comparação entre Pares

Variação de preço

ESPERION THERAPEUTICS INC Previsão

Preço-alvo

By TipRanks

638.64% parte superior

Previsão para 12 meses

Média 6.5 USD  638.64%

Máximo 16 USD

Mínimo 2 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para ESPERION THERAPEUTICS INC - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

6 ratings

4

Comprar

1

Manter

1

Vender

Pontuação Técnica

By Trading Central

0.8191 / 0.95Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre ESPERION THERAPEUTICS INC

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.